Differential effects of an o-glcnacase inhibitor on tau phosphorylation

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Yu, Yang ^a   Zhang, Lan ^a   Li, Xiaojing ^a   Run, Xiaoqin ^a   Liang, Zhihou ^a   Li, Yi ^a   Liu, Ying ^a   Lee, Moon H ^a   Grundke Iqbal, Inge ^a   Iqbal, Khalid ^a   Vocadlo, David J ^b   Liu, Fei ^a   Gong, Cheng Xin ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOSIDASE INHIBITOR; N ACETYLGLUCOSAMINE; PROTEIN KINASE B; SERINE; TAU PROTEIN; THIAMET G; THREONINE; UNCLASSIFIED DRUG; BETA N ACETYLHEXOSAMINIDASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HEXOSAMINIDASE C; PROTEIN KINASE; PYRAN DERIVATIVE; THIAZOLE DERIVATIVE;

ACYLATION; ADULT ANIMAL; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; HIPPOCAMPUS; LATERAL BRAIN VENTRICLE; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT; STEM CELL; WESTERN BLOTTING; ANIMAL; BRAIN; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NERVE CELL; PHOSPHORYLATION; TRANSGENIC MOUSE;

MAMMALIA; MUS;

ACYLATION; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; BRAIN; CELLS, CULTURED; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, TRANSGENIC; NEURONS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRANS; RATS; TAU PROTEINS; THIAZOLES;

EID: 84859819548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035277     Document Type: Article

References (45)

1. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I, (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118: 53-69.
2. Lovestone S, Reynolds CH, (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324.
3. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR, (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130.
4. Gong CX, Grundke-Iqbal I, Iqbal K, (2010) Targeting tau protein in Alzheimer's disease. Drugs Aging 27: 351-365.
5. Hernandez F, de Barreda EG, Fuster-Matanzo A, Goni-Oliver P, Lucas JJ, et al. (2009) The role of GSK3 in Alzheimer disease. Brain Res Bull 80: 248-250.
6. Gong CX, Grundke-Iqbal I, Iqbal K, (1994) Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61: 765-772.
7. Goedert M, Jakes R, Qi Z, Wang JH, Cohen P, (1995) Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem 65: 2804-2807.
8. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC, (1996) Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17: 1201-1207.
9. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX, (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942-1950.
10. Planel E, Yasutake K, Fujita SC, Ishiguro K, (2001) Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 276: 34298-34306.
11. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K, (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61: 921-927.
12. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM, (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168: 402-412.
13. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R, (2001) A gene expression profile of Alzheimer's disease. DNA Cell Biol 20: 683-695.
14. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, et al. (2004) Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63: 287-301.
15. Lefebvre T, Ferreira S, Dupont-Wallois L, Bussiere T, Dupire MJ, et al. (2003) Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins-a role in nuclear localization. Biochim Biophys Acta 1619: 167-176.
16. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX, (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101: 10804-10809.
17. Robertson LA, Moya KL, Breen KC, (2004) The potential role of tau protein O-glycosylation in Alzheimer's disease. J Alzheimers Dis 6: 489-495.
18. Li X, Lu F, Wang JZ, Gong CX, (2006) Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 23: 2078-2086.
19. Liu F, Shi J, Tanimukai H, Gu J, Gu J, et al. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132: 1820-1832.
20. Butkinaree C, Park K, Hart GW, (2010) O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta 1800: 96-106.
21. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, et al. (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 175: 2089-2098.
22. Gong CX, Iqbal K, (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15: 2321-2328.
23. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, et al. (2008) A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4: 483-490.
24. Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, et al. (2002) Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 22: 133-141.
25. Planel E, Richter KE, Nolan CE, Finley JE, Liu L, et al. (2007) Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27: 3090-3097.
26. Run X, Liang Z, Zhang L, Iqbal K, Grundke-Iqbal I, et al. (2009) Anesthesia induces phosphorylation of tau. J Alzheimers Dis 16: 619-626.
27. Bensadoun A, Weinstein D, (1976) Assay of proteins in the presence of interfering materials. Anal Biochem 70: 241-250.
28. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I, (2007) Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 28: 1148-1162.
29. Paez J, Sellers WR, (2003) PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 115: 145-167.
30. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, et al. (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19: 1221-1229.
31. Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M, (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19: 453-460.
32. Tatebayashi Y, Iqbal K, Grundke-Iqbal I, (1999) Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J Neurosci 19: 5245-5254.
33. Ksiezak-Reding HPH, Feinstein B, Pasinetti GM, (2003) Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim Biophys Acta 1639: 159-168.
34. Dauphinee SM, Ma M, Too CK, (2005) Role of O-linked beta-N-acetylglucosamine modification in the subcellular distribution of alpha4 phosphoprotein and Sp1 in rat lymphoma cells. J Cell Biochem 96: 579-588.
35. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, et al. (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451: 964-969.
36. Luo B, Soesanto Y, McClain DA, (2008) Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol 28: 651-657.
37. Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW, (2009) Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 285: 5204-5211.
38. Arias EB, Kim J, Cartee GD, (2004) Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes 53: 921-930.
39. Macauley MS, Bubb AK, Martinez-Fleites C, Davies GJ, Vocadlo DJ, (2008) Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J Biol Chem 283: 34687-34695.
40. Macauley MS, He Y, Gloster TM, Stubbs KA, Davies GJ, et al. (2010) Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes. Chem Biol 17: 937-948.
41. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqba I, et al. (1998) Maximal inhibition of tau binding to microtubules requires the phosphorylation of tau at both Thr 231 and Ser 262. Neurobiol Aging 19: S124-524.
42. Alonso AD, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K, (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279: 34873-34881.
43. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, et al. (2007) Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 26: 3429-3436.
44. Pei JJ, Gong CX, Iqbal K, Grundke-Iqbal I, Wu QL, et al. (1998) Subcellular distribution of protein phosphatases and abnormally phosphorylated tau in the temporal cortex from Alzheimer's disease and control brains. J Neural Transm 105: 69-83.
45. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, et al. (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56: 70-78.